Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Drug Name | LVGN3616 |
Trade Name | |
Synonyms | LVGN-3616|LVGN 3616|pradusinstobart |
Drug Descriptions |
LVGN3616 is a humanized monoclonal antibody that targets PD-1 (PDCD1), potentially resulting in restoration of T-cell mediated immune response (NCI Thesaurus). |
DrugClasses | Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 109 |
CAS Registry Number | NA |
NCIT ID | C178280 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Bevacizumab + Cyclophosphamide + LVGN3616 + LVGN6051 | Bevacizumab Cyclophosphamide LVGN3616 LVGN6051 | 0 | 1 |
Bevacizumab + Cyclophosphamide + LVGN3616 + LVGN6051 + LVGN7409 | Bevacizumab Cyclophosphamide LVGN3616 LVGN6051 LVGN7409 | 0 | 1 |
LVGN3616 | LVGN3616 | 0 | 0 |
LVGN3616 + LVGN6051 + LVGN7409 + Nab-paclitaxel | LVGN3616 LVGN6051 LVGN7409 Nab-paclitaxel | 0 | 1 |
LVGN3616 + LVGN6501 + Nab-paclitaxel | LVGN3616 LVGN6501 Nab-paclitaxel | 0 | 1 |